0001140361-22-008674.txt : 20220309
0001140361-22-008674.hdr.sgml : 20220309
20220309175854
ACCESSION NUMBER: 0001140361-22-008674
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220307
FILED AS OF DATE: 20220309
DATE AS OF CHANGE: 20220309
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fong Bryant
CENTRAL INDEX KEY: 0001542298
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36728
FILM NUMBER: 22726627
MAIL ADDRESS:
STREET 1: 2170 VALLEJO STREET #101
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94123
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC.
CENTRAL INDEX KEY: 0001368514
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 562590442
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
BUSINESS PHONE: (201) 478-5552
MAIL ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
FORMER COMPANY:
FORMER CONFORMED NAME: R&R ACQUISITION VI, INC
DATE OF NAME CHANGE: 20060707
4
1
form4.xml
FORM 4
X0306
4
2022-03-07
0001368514
ADMA BIOLOGICS, INC.
ADMA
0001542298
Fong Bryant
C/O ADMA BIOLOGICS, INC.
465 STATE ROUTE 17
RAMSEY
NJ
07446
true
Common Stock
2022-03-07
4
A
0
26586
0
A
34086
D
Common Stock
1433304
I
See Footnote
Employee Stock Option (right to buy)
1.67
2022-03-07
4
A
0
53172
0
A
2032-03-07
Common Stock
53172
53172
D
These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.
Includes (i) 26,586 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); and (ii) 7,500 shares of common stock owned by the reporting person.
Represents shares held by Biomark Capital Fund ("Biomark Capital"). Mr. Fong is a Managing Director and General Partner at Biomark Capital and may be deemed the beneficial owner of such shares.
The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
/s/ Bryant Fong, by Brian Lenz as Attorney-in-fact
2022-03-09